Carboplatin with or without Atezolizumab in Treating Patients with Stage IV Triple Negative Breast Cancer
- Patients must provide informed written consent
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Clinical stage IV (metastatic) ER, PR, HER2 negative invasive mammary carcinoma, previously documented by histological analysis and that meets the following criteria: * HER2 negativity is defined as any of the following by local laboratory assessment: in-situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 < 2.0 or single probe average HER2 gene copy number < 4 signals/cell), or IHC 0 or IHC 1+ (if more than one test result is available and not all results meet the inclusion criterion definition, all results should be discussed with the protocol chair to establish eligibility of the patient) * ER and PR negativity are defined as =< 10% of cells expressing hormonal receptors via IHC analysis
- Willing to undergo biopsy of a metastatic lesion (in patients with reasonably accessible metastatic lesions such as chest wall, skin, subcutaneous tissue, lymph nodes, bones, peripheral lung, and liver metastases)
- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by RECIST criteria version (v)1.1
- Zero or one prior chemotherapy regimens for metastatic disease
- No prior treatment with carboplatin in the metastatic setting; carboplatin in neoadjuvant/adjuvant setting may be allowed if prior treatment with carboplatin was completed at least one year prior to initiation of this study and after discussion with the study chair
- Absolute neutrophil count (ANC) >= 1500/mm^3 (to be obtained less than 28 days from initiation of study drug)
- Platelet count >= 100,000/mm^3 (to be obtained less than 28 days from initiation of study drug)
- Calculated creatinine clearance >= 30 mL/min using the Cockcroft and Gault formula (to be obtained less than 28 days from initiation of study drug)
- Bilirubin =< 2.5 x upper limits of normal if no liver metastases present; serum total bilirubin must be =< 3 x upper limits of normal for patients with Gilbert disease; total bilirubin =< 5 x upper limits of normal if liver metastases present (to be obtained less than 28 days from initiation of study drug)
- Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) =< 2.5 x upper limits of normal if no liver metastases present; SGOT, SGPT =< 5 x upper limits of normal if liver metastases present (to be obtained less than 28 days from initiation of study drug)
- Alkaline phosphatase =< 2.5 x upper limits of normal if no liver metastases present; alkaline phosphatase =< 5 x upper limits of normal if liver metastases present (to be obtained less than 28 days from initiation of study drug)
- For patients who are not postmenopausal (women) or surgically sterile (absence of ovaries and/or uterus or vasectomy), agreement to remain abstinent or to use two adequate methods of contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal ligation), during the treatment period and for at least 30 days after the last dose of study treatment; hormone based oral contraceptives are not allowed on study; postmenopausal is defined as: * Age >= 55 years * Age =< 55 years and amenorrheic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone and estradiol in the postmenopausal range
- Subjects must complete all baseline screening assessments; the biopsy may be obtained before or after the patient is deemed eligible by administrative review, but must be before administration of study drugs on cycle 1, day 1
- CANCER-SPECIFIC EXCLUSION CRITERIA
- Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to randomization
- Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases, provided all of the following criteria are met: measurable disease outside the CNS, only supratentorial and cerebellar metastases are allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord), no evidence of progression or hemorrhage after completion of CNS-directed therapy, no ongoing requirement for dexamethasone as therapy for CNS disease, (anticonvulsants at a stable dose are allowed), no stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomization
- Leptomeningeal disease
- Uncontrolled tumor-related pain: patients requiring narcotic pain medication must be on a stable regimen at registration; symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization; patients should be recovered from the effects of radiation; there is no required minimum recovery period; asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomization
- Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy; patients who are receiving denosumab must discontinue denosumab use and replace it with a bisphosphonate instead while on study; patients receiving a bisphosphonate for skeletal metastases are not excluded and can continue treatment
- Malignancies other than triple negative breast cancer (TNBC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
- Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biological therapy) other than the ones specified in the protocol; any standard or investigational drugs should be discontinued 2 weeks prior to the first dose of study medication
- GENERAL MEDICAL EXCLUSION CRITERIA
- Women only: pregnancy or lactation
- Evidence of significant uncontrolled concomitant disease that in the opinion of the investigator could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
- Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina; patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded; patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
- Severe infection requiring systemic treatment within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
- Major surgical procedure within 4 weeks prior to randomization or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis; placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted
- History of severe reactions (e.g. allergic, anaphylactic, or other hypersensitivity) to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjogren’s syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study; patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible for this study
- Prior allogeneic stem cell or solid organ transplantation
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Positive test for human immunodeficiency virus (HIV) (testing required prior to registration)
- Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
- Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
- Active tuberculosis
- Receipt of a live, attenuated vaccine within 4 weeks prior to initiation of study drug (cycle 1, day 1 [C1D1]) or anticipation that such a live, attenuated vaccine will be required during the study
- Prior treatment with CD137 agonists, anti−PD-1, or anti−PD-L1 therapeutic antibody or pathway-targeting agents
- Treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-2) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
- Treatment with systemic corticosteroids or other systemic immunosuppressant medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor [TNF] agents) within 2 weeks prior to cycle 1, day 1, or anticipated requirement for systemic immunosuppressive medications during the trial; patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study. Patients on a stable low dose (=< 10 mg) daily prednisone or equivalent are allowed on study. Patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using magnetic resonance imaging (MRI); the use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed
- Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
District of Columbia
I. To evaluate the efficacy, as measured by median progression free survival (PFS) of carboplatin + atezolizumab (using Response Evaluation Criteria in Solid Tumors [RECIST]) versus carboplatin alone (using RECIST) in patients with triple negative metastatic breast cancer.
I. To determine overall response rate (ORR).
II. To evaluate the efficacy, as measured by clinical benefit rate (CBR), of carboplatin + atezolizumab versus carboplatin alone in patients with triple negative metastatic breast cancer.
III. To determine the duration of response (DOR) for patients achieving a partial or complete response.
IV. To evaluate the overall survival (OS) of carboplatin + atezolizumab versus carboplatin alone in patients with triple negative metastatic breast cancer.
V. To evaluate PFS, ORR, and DOR based on immune related Response Evaluation Criteria in Solid Tumors (irRECIST) as assessed by central imaging review.
I. Tumor infiltrating lymphocyte frequency and phenotype (TILs) at baseline.
II. PD-L1 expression from the baseline pre-treatment tissue and at progression lesion, performed by immunohistochemistry (IHC) (SP142 clone) using a facility designated by the supporter (Genentech).
III. HER2 (IHC, fluorescence in situ hybridization [FISH]) and estrogen receptor (ER)/progesterone receptor (PR) levels (IHC) from a metastatic site.
IV. Perform ribonucleic acid-sequencing (RNA-seq) to determine non-synonymous mutation burden in expressed genes and gene expression to assign a triple negative subtype at baseline for correlations with clinic outcome.
V. Immune phenotyping (IHC) for markers of T cell subsets and activation (CD4, CD8, FoxP3, CD25, Glut1) and exhaustion (PD1, CTLA4) and test feasibility of flow cytometric analyses to include additional markers.
VI. To assess the effect of BRCA mutations on response to the study drugs.
VII. To evaluate the effect of steroids on the efficacy of atezolizumab.
VIII. To assess the prognostic effects of TILs on PFS and CBR in patients receiving atezolizumab.
IX. To determine the correlation between low muscle mass and tumor immunophenotype by PDL1 expression, TIL frequency, tumor mutation burden, T cell activation, and T cell exhaustion.
X. To determine the correlation between low muscle attenuation and tumor immunophenotype by PDL1 expression, TIL frequency, tumor mutation burden, T cell activation, and T cell exhaustion.
XI. To determine the correlation between adipose mass and tumor immunophenotype by PDL1 expression, TIL frequency, tumor mutation burden, T cell activation, and T cell exhaustion.
XII. To determine the prognostic impact of low muscle mass (LMM), low muscle attenuation (LMA), and adiposity on progression free survival in patients receiving atezolizumab (anti-PDL1).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive atezolizumab intravenously (IV) over 30-60 minutes and carboplatin IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients receive carboplatin as in Arm 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
After completion of study treatment, patients are followed up at 30 days and then yearly for 3 years.
Trial Phase Phase II
Trial Type Treatment
Vanderbilt University / Ingram Cancer Center
Vandana Gupta Abramson
- Primary ID VICCBRE15136
- Secondary IDs NCI-2017-01150
- Clinicaltrials.gov ID NCT03206203